title: ASCO-CAP guidelines for breast predictive factor testing: an update.
abstract: This brief report compares and contrasts the American Society of Clinical Oncology/College of American Pathologists guidelines for breast cancer predictive factor testing including the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor, type 2, erbB2 Guideline published in 2007 and the recently published Guideline for Estrogen Receptor and Progesterone Receptor Testing by Immunohistochemistry, published in 2011.
authors.affiliation: Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT 84143, USA. Elizabeth.hommond@imail.org
authors.forename: M Elizabeth Hale
authors.initials: ME
authors.lastname: Hammond
mesh_terms: D001943:Breast Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology*; D055088:Early Detection of Cancer; D047629:Estrogen Receptor beta / Q000276:immunology / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods / Q000592:standards*; D017410:Practice Guidelines as Topic; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology / Q000378:metabolism; D011980:Receptors, Progesterone / Q000276:immunology / Q000378:metabolism; D012015:Reference Standards; D014481:United States
chemical_list: D047629:Estrogen Receptor beta; D018719:Erb-b2 Receptor Tyrosine Kinases; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human